Geode Capital Management LLC raised its holdings in iBio, Inc. (NYSE:IBIO – Free Report) by 52.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 83,797 shares of the company’s stock after buying an additional 28,775 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of iBio worth $205,000 at the end of the most recent quarter.
iBio Price Performance
Shares of NYSE:IBIO opened at $1.01 on Friday. The business has a 50-day moving average of $3.18 and a two-hundred day moving average of $2.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.76 and a current ratio of 1.76. iBio, Inc. has a 12 month low of $0.64 and a 12 month high of $6.89.
Analysts Set New Price Targets
Separately, StockNews.com upgraded shares of iBio to a “sell” rating in a report on Tuesday, March 18th.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
See Also
- Five stocks we like better than iBio
- ESG Stocks, What Investors Should Know
- Magnificent 7 Stocks Send a Dire Warning to Markets
- Stock Dividend Cuts Happen Are You Ready?
- Why Spotify Stock Still Has Room to Run in 2025
- How to Use Stock Screeners to Find Stocks
- Buy the Dip: Top Tech Stocks Analysts Say Are Undervalued
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
